Xentria

About Xentria

Xentria Inc., established in 2020, operates as a clinical-stage biopharmaceutical company with its headquarters in Chicago. The company was spun out of Meitheal Pharmaceuticals in 2020 to develop high-value drugs with patent protection. The founding President is Tom Shea, who also serves as the CEO of Meitheal Pharmaceutical. His background includes roles at Sagent Pharmaceuticals and Fresenius Kabi, with a focus on global partnerships, supply chain, and product development.

Xentria's business model is centered on building a pipeline of therapeutics to address unmet needs for patients with rare diseases, immunologic disorders, and oncological conditions. The company forges partnerships with biopharmaceutical communities to advance challenging drug development, particularly in higher-risk, early-stage projects. A significant part of its strategy involves an exclusive licensing agreement with Meitheal Pharmaceuticals to commercialize its lead candidate, XTMAB-16, in North America. This deal includes up-front payments, milestone-based payments totaling up to $80 million, and potential royalties exceeding $600 million. In October 2022, Xentria secured a $25 million growth equity funding round to advance its pipeline and support the clinical development of XTMAB-16.

The company's lead product is XTMAB-16, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNFα). It is being developed as a potential treatment for pulmonary sarcoidosis, a chronic, multisystem inflammatory disorder with limited treatment options. XTMAB-16 received FDA Orphan Drug Designation in November 2020 and is currently in Phase 2 clinical trials. In addition to its lead candidate, Xentria's portfolio includes a range of biosimilars in clinical and early-stage development for endocrinology and hematology/oncology. The company also engages in co-development partnerships, including a collaboration with New York University for a cardiovascular disease therapeutic and development of a ligand-targeted drug imaging technology for oncology. In May 2025, Xentria launched Xturnpoint, a venture partnering studio designed to support early-stage therapeutic innovators by providing capital, scientific guidance, and development infrastructure.